228 related articles for article (PubMed ID: 17360108)
1. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
[TBL] [Abstract][Full Text] [Related]
2. [Effects of mTOR siRNA on mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cells and the growth of transplanted tumor in nude mice].
Liu MY; Hou GQ; Zhang Y; Bei WJ; Yan AH
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):334-9. PubMed ID: 21875460
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
4. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
5. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL
Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268
[TBL] [Abstract][Full Text] [Related]
6. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
7. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma.
Lu Z; Peng K; Wang N; Liu HM; Hou G
J Immunol Res; 2016; 2016():7828916. PubMed ID: 27595116
[TBL] [Abstract][Full Text] [Related]
10. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
12. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
13. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
14. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors.
Drayer AL; Olthof SG; Vellenga E
Stem Cells; 2006 Jan; 24(1):105-14. PubMed ID: 16123382
[TBL] [Abstract][Full Text] [Related]
17. Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade.
Liu Y; Hidayat S; Su WH; Deng X; Yu DH; Yu BZ
Cell Biochem Funct; 2007; 25(1):45-53. PubMed ID: 16927414
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
Han B; Tong J; Zhu MJ; Ma C; Du M
Mol Reprod Dev; 2008 May; 75(5):810-7. PubMed ID: 18033679
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
